secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANUWAVE Health, Inc. (SNWV)
CIK:        0001417663
Form:       8-K
Filed at:   2025-01-14T23:59:59+00:00
Accession:  0001628280-25-001397
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanuwave announces preliminary Q4 2024 revenue of $10.1-10.3M, record high, up 44-47% YoY
--------------------------------------------------------------------------------

- Q4 2024 revenue expected $10.1-10.3M, highest quarterly revenue in company history; increase of 44-47% YoY.
- UltraMist revenue up >54% vs Q4 2023, representing ~98% of total Q4 revenue; applicator sales all-time record ~58% of total.
- Full year 2024 preliminary revenue $32.4-32.6M, up 59-60% vs 2023.
- CEO Morgan Frank cites third consecutive record quarter and 'breakout year' targeting rapid profitable growth.
- Company expects to release complete Q4 and FY2024 results in March 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1417663/000162828025001397/0001628280-25-001397-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1417663/000162828025001397/snwv-20250113.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-001397

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer